Gilead Sciences

Open: 82.86 Close: 83.99 Change: 1.13

How to know if Gilead Sciences Company Inc Stock is a risky investment without reading the whole internet.

How much time have you spent trying to decide whether investing in Gilead Sciences? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Gilead Sciences are: …

Concept Map

Semantic Network

Stock Summary

Gilead Sciences, Inc. discovers, develops, and commercializes medicines in the areas of unmet medical need. The company provides Biktarvy, Genvoya, Descovy, Descogna, Odefsey,.

Today's Summary

Gilead Sciences Inc. (Gild) stock climbed 2% in extended trading Tuesday after the pharmaceutical company reported quarterly results that topped analyst revenue and earnings estimates. The percentage of shares that are sold short has grown since its last report. The company currently falls under Mega-Cap category.

Today's News

Gilead Sciences Inc. (Gild) stock price, quote, news & analysis. gilead sciences, inc. (gild) Stock Price, Quote, News & Analysis. Join now Search for Symbols, analysts, keywords Log in GILD. Gilead Sciences Inc.s GILD, -0.65% stock climbed 2% in extended trading Tuesday after the pharmaceutical company reported quarterly results that topped analyst revenue and earnings estimates. The percentage of shares that are sold short has grown since its last report. District Judge Jeffrey White in Oakland, California, ruled that Gilead Sciences Inc must face a potential class action lawsuit accusing it of paying off Indian generic manufacturer Cipla Ltd not to compete with its HIV preventative medicine Truvada. Gilead Sciences, Inc. (GILD) will gilead sciences, inc. (gild) outperform the rest of the stocks in the healthcare sector? Will Gileads $848M Bet on Compugens Revolutionary Therapy GileAD is a good investment. Analysts arrive at stock ratings after researching the public financial statements of Gilead Sciences, talking to its executives and customers, or listening to those companies conference calls. The company currently falls under Mega-Cap category. Gilead Sciences management efficiency ratios could be used to measure how well Gileade Sciences manages its routine affairs as well as how well it operates its assets and liabilities. Analysts from Wall Street are used by the market to judge the value and potential of its stock. At present, GileAd Sciences Revenue to Assets are projected to slightly decrease. Gilead Sciences Trailing 12 Months Earnings per Share Projection vs Actual Actual Actual Earning per Share of Gileade Sciences. Expected EPS Projection is what analysts predict the companys earnings will be in the future. The higher the earnings per share, the better is its profitability. Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The market value of GileAD Sciences is measured differently than its book value, which is the value of the company. Gilead Sciences is carrying a Zacks Rank of #3 (Hold) Currently, the company is holding a Forward P/E ratio of 11.36. The investment community will be paying close attention. Gilead Sciences has risen higher in 18 of those 31 years over the subsequent 52-week period, corresponding to a historical accuracy of 58.06%. Over the next 52 weeks, the stock has on average historically risen by 24.4% based on the past 31 years of stock performance.

Stock Profile

"Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Merck & Co, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California."

Keywords

This document will help you to evaluate Gilead Sciences without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Gilead Sciences are: Sciences, Gilead, stock, company, well, value, Inc, and the most common words in the summary are: gilead, science, stock, job, market, best, price, . One of the sentences in the summary was: (Gild) stock climbed 2% in extended trading Tuesday after the pharmaceutical company reported quarterly results that topped analyst revenue and earnings estimates. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #gilead #science #stock #job #market #best #price.